Vascular disrupting agents in clinical development

British Journal of Cancer

Volumn 96, Issue 8, 2007, Pages 1159-1165

  Hinnen, P ^a   Eskens, F A L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis inhibitors; Clinical trials; Vascular disrupting drugs

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ABT 571; ANALGESIC AGENT; AURISTATIN PE; CARBOPLATIN; CISPLATIN; COMBRETASTATIN; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; DOXORUBICIN; FLAVONOID; MN 029; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; OXALIPLATIN; PACLITAXEL; PEMETREXED; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TUBULIN MODULATOR; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANAPLASTIC CARCINOMA; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTERY BLOOD FLOW; ATAXIA; BLOOD TOXICITY; BLURRED VISION; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CARCINOGENESIS; CARCINOMA; CARDIOTOXICITY; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTRAST ENHANCEMENT; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DYSPNEA; ECG ABNORMALITY; FATIGUE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; ILEUS; INJECTION SITE PAIN; INTESTINE ISCHEMIA; ISCHEMIC HEART DISEASE; KIDNEY CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SENSORIMOTOR NEUROPATHY; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; SLURRED SPEECH; SOLID TUMOR; SYNCOPE; TACHYCARDIA; THROMBOCYTOPENIA; THYROID CANCER; TREMOR; TUMOR NECROSIS; TUMOR VASCULARIZATION; URINE INCONTINENCE; UTERINE CERVIX CARCINOMA; VISUAL DISORDER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; ORGANOPHOSPHORUS COMPOUNDS; REGIONAL BLOOD FLOW; STILBENES; TUBULIN MODULATORS; XANTHONES;

EID: 34247249906     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603694     Document Type: Short Survey

References (51)

1. Baguley BC, Zhuang L, Kestell P (1997) Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicines: relation to vascular effects. Oncol Res 9: 55-60
2. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM (1998) Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77: 1761-1767
3. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest E (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24: 1491-1498
4. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ (2005) Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 11: 1527-1533
5. Chaplin DJ, Dougherty GJ (1999) Tumour vasculature as a target for cancer therapy. Br J Cancer 80(Suppl 1): 57-64
6. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 86: 1937-1942
7. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, Stambler BS, Remick SC (2004) Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10: 96-100
8. Corbett TH, Bissery MC, Wozniak A, Plowman J, Polin L, Tapazoglou E, Dieckman J, Valeriote F (1986) Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs 4: 207-220
9. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 57: 1829-1834
10. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253
11. DeJonge MJ, van der Gaast A, Planting AS, van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J (2005) Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 10: 3806-3813
12. Demers B, Vrignaud P, Bissery M (2006) In vivo synergy combining oxaliplatin with AVE8062, a vascular-disrupting agent. J Clin Oncol 24(suppl): 607s (abstract 13074)
13. Denekamp J (1982) Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45: 136-139
14. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416
15. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356: 125-134
16. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676
17. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
18. Gabra H (2006) Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. J Clin Oncol 24(Suppl): 263s (abstract 5032)
19. Gadgeel SM, LoRusso P, Wozniak AJ, Wheeler C (2002) A dose escalation study of the novel vascular targeting agent ZD6126 in patients with solid tumours. J Clin Oncol 21(Suppl): 110a (abstract 438)
20. Galbraith SM, Maxwell RJ, Lodge MA (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21: 2831-2842
21. Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W (2006) A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol 8: 1309-1313
22. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML (2006) The pharmacokinetics and safety of ABT-751, a novel orally bioavailable sulfonamide antimitotic agent: results of a phase I study. Clin Cancer Res 9: 2834-2840
23. Heeckeren van WJ (2006) Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for the oncologists to get to know their cardiologists? J Clin Oncol 24: 1485-1488
24. Hori K, Saito S, Kubota K (2002) A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86: 1604-1614
25. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
26. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88: 1844-1850
27. Kakolyris S, Fox S, Koukourakis M, Giatromanolaki A, Brown N, Leek RD, Taylor M, Leigh IM, Gatter KC, Harris AL (2000) Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assesed by expression of a novel basement membrane component, LH39. Br J Cancer 82: 844-851
28. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739
29. Koehne C, Bajetta E, Lin E, van Cutsem E, Hecht J, Douillard J, Morre M, Germond C, Laurent D (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol 24(Suppl): 148s (abstract 3508)
30. Konerding MA, Fait E, Gaumann A (2001) 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 84: 1354-1362
31. LoRusso S, Gadgeel SM, Wozniak AJ (2002) A phase I dose escalation trial of ZD6126, a novel vascular targeting agent, in patients with cancer refractory to other treatments. Proc AACR-NCI-EORTC (abstract 36)
32. McGown AT, Fox BW (1989) Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anti Cancer Drud Des 3: 249-254
33. McKeage M (2006) Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). J Clin Oncol 24(Suppl): 389s (abstract 7102)
34. Motzer RJ, Hutson TE, Tomzak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier M, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib vs Interferon Alfa in metastatic renal cell carcinoma. N Engl J Med 356: 115-124
35. Ozawa Y, Sugi NH, Nagasu T, Owa T, Wantanabe T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K (2001) E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo. Eur J Cancer 37: 2275-2282
36. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Phoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL (2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 10: 3124-3129
37. Ricart AD, Cooney M, Sarantopoulos J, Brell J, Locke KW, Gammans RE, Medina G, Zambito A, Tolcher W, Remick SC (2006) A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors. J Clin Oncol 24(Suppl): 144s (abstract 3096)
38. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM (2003a) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21: 2815-2822
39. Rustin GJS, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G (2003b) 5,6-dimethylxanthenone-4- acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88: 1160-1167
40. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lillenbaum R, Johnson DH (2006) Paclitaxel-Carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542-2550
41. Schoffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cherverton P, Wanders J, Oguma T, Atsumi R, Satomi M (2004) Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-h intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 4: 671-679
42. Shi W, Siemann DW (2005) Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res 25: 3899-3904
43. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11: 416-420
44. Siemann DW, Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Rad Oncol 60: 1233-1240
45. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ (2003) Phase I trial of the antivasular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered blood flow. J Clin Oncol 21: 4428-4438
46. Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC (1991) Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51: 77-81
47. Tolcher AW, Forero L, Celio P, Hammond LA, Patnaik A, Hill M, Verat-Follet C, Haacke M, Besenval M, Rowinsky EK (2003) Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days. J Clin Oncol 22(Suppl): 208 (abstract 834)
48. Tozer GM, Lewis S, Michalowski A, Aber V (1990) The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br J Cancer 61: 250-257
49. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ (1999) Combretastatin A-4-phosphate as a tumor vascular targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-1634
50. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Investigation 115: 2992-3006
51. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434